Clinical Trial Update: Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a fixed-dose combination of ledipasvir/sofosbuvir with ribavirin or GS-9669 in Chronic Hepatitis C Virus infection shows completed resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GS-9669 (GS-9669)
• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic HCV Infection | Phase 2 | Status: COMPLETED | Results posted: 2015-05-21